MedinCell S.A. (FRA:MEB)

Germany flag Germany · Delayed Price · Currency is EUR
25.80
+0.10 (0.39%)
Last updated: Dec 5, 2025, 9:59 AM CET
58.87%
Market Cap 860.44M
Revenue (ttm) 27.73M
Net Income (ttm) -18.44M
Shares Out n/a
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 25.50
Previous Close 25.70
Day's Range 25.50 - 26.14
52-Week Range 12.06 - 37.82
Beta n/a
RSI 30.92
Earnings Date Dec 9, 2025

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ... [Read more]

Industry Pharmaceutical Preparations
Founded 2003
Employees 131
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol MEB
Full Company Profile

Financial Performance

In 2024, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2023.

Financial Statements

News

There is no news available yet.